Eli Lilly reported $98 million in second-quarter sales fo | Eli Lilly reported $98 million in second-quarter sales for Foundayo, its newly launched oral GLP-1 treatment, lagging far behind rival Novo Nordisk's Wegovy pill.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into…
Eli Lilly plans to launch its oral obesity treatment Foundayo in Europe by the end of this year or early 2027, focusing on the…
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward…
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish…
Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.
Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
